These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 11020002)

  • 1. Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.
    Di Marco V; Almasio P; Vaccaro A; Ferraro D; Parisi P; Cataldo MG; Di Stefano R; Craxì A
    J Hepatol; 2000 Sep; 33(3):456-62. PubMed ID: 11020002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT).
    Poynard T; Marcellin P; Lee SS; Niederau C; Minuk GS; Ideo G; Bain V; Heathcote J; Zeuzem S; Trepo C; Albrecht J
    Lancet; 1998 Oct; 352(9138):1426-32. PubMed ID: 9807989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group.
    Shiffman ML; Hofmann CM; Gabbay J; Luketic VA; Sterling RK; Sanyal AJ; Contos MJ; Ryan MJ; Yoshida C; Rustgi V
    Am J Gastroenterol; 2000 Oct; 95(10):2928-35. PubMed ID: 11051370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon.
    Almasio PL; Di Marco V; Bonura C; Fuschi P; Camma C; Lo Iacono O; Artini M; Natoli C; Di Stefano R; Levrero M; Craxi A
    Dig Dis Sci; 1999 May; 44(5):1013-9. PubMed ID: 10235612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.
    Enríquez J; Gallego A; Torras X; Pérez-Olmeda T; Diago M; Soriano V; Luján MS; García-Samaniego J
    J Viral Hepat; 2000 Nov; 7(6):403-8. PubMed ID: 11115050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group.
    Cavalletto L; Chemello L; Donada C; Casarin P; Belussi F; Bernardinello E; Marino F; Pontisso P; Gatta A; Alberti A
    J Hepatol; 2000 Jul; 33(1):128-34. PubMed ID: 10905596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C.
    Buti M; Olive G; Stalgis C; Esteban R; Guardi J
    Dig Dis Sci; 2000 Apr; 45(4):685-9. PubMed ID: 10759235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term lymphoblastoid interferon-alpha therapy for non-cirrhotic chronic hepatitis C: an Italian multicentre study on dose and duration of IFN alpha treatment.
    Piccinino F; Felaco FM; Sagnelli E; Aprea L; Messina V; Pasquale G; Filippini P; Scolastico C
    Res Virol; 1998; 149(5):283-91. PubMed ID: 9879606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone.
    Min AD; Jones JL; Esposito S; Lebovics E; Jacobson IM; Klion FM; Goldman IS; Geders JM; Tobias H; Bodian C; Bodenheimer HC
    Am J Gastroenterol; 2001 Apr; 96(4):1143-9. PubMed ID: 11316161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose interferon-alpha2b induction therapy in combination with ribavirin for treatment of chronic hepatitis C in patients with non-response or relapse after interferon-alpha monotherapy.
    Hass HG; Kreysel C; Fischinger J; Menzel J; Kaiser S
    World J Gastroenterol; 2005 Sep; 11(34):5342-6. PubMed ID: 16149143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction.
    Di Marco V; Ferraro D; Almasio P; Vaccaro A; Parisi P; Cappello M; Cino N; Di Stefano R; Craxì A
    J Viral Hepat; 2002 Sep; 9(5):354-9. PubMed ID: 12225330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early addition of ribavirin to interferon in chronic hepatitis C not responsive to interferon monotherapy.
    Bellobuono A; Mondazzi L; Tempini S; Chiodo F; Magliano E; Furione L; Idéo G
    J Hepatol; 2000 Sep; 33(3):463-8. PubMed ID: 11020003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.
    Bell H; Hellum K; Harthug S; Myrvang B; Ritland S; Maeland A; von der Lippe B; Bjøro K; Skaug K; Gutigard BG; Raknerud N; Simmonds P
    Scand J Gastroenterol; 1999 Feb; 34(2):194-8. PubMed ID: 10192200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial.
    Poynard T; Marcellin P; Bissery A; Myers RP; Moussalli J; Degos F; Dhumeaux D; Riachi G; Bronowicki JP; Brissot P; Buffet C; Serfaty L; Naveau S; Sogni P; Beaugrand M; Gayno S; Larrey D; Samuel D; Eugene C; Pol S; Bedossa P; Daurat V; Chaumet-Riffaud P;
    J Viral Hepat; 2003 May; 10(3):197-204. PubMed ID: 12753338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of the efficacy of an induction dose of interferon-alpha2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C.
    Pérez R; Jiménez M; Crespo J; Diago M; Enríquez J; Vaquero P; Solá R; Olcoz JL; Romero M; Salmerón J; Blanco MI; Oña M; Melón S; Rodrigo L;
    J Viral Hepat; 2003 Nov; 10(6):437-45. PubMed ID: 14633177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy.
    Steindl-Munda P; Ferenci P; Brunner H; Nachbaur K; Datz C; Gschwantler M; Hofer H; Stauber R; Hackl F; Jessner W; Rosenbeiger M; Gangl A; Vogel W;
    Liver Int; 2003 Aug; 23(4):269-75. PubMed ID: 12895267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C.
    Fattovich G; Zagni I; Fornaciari G; Minola E; Fabris P; Boccia S; Giusti M; Abbati G; Felder M; Rovere P; Redaelli A; Tonon A; Montanari R; Paternoster C; Distasi M; Castagnetti E; Tositti G; Rizzo C; Suppressa S; Pantalena M; Lomonaco L; Scattolini C; Tagger A
    J Viral Hepat; 2003 Mar; 10(2):111-7. PubMed ID: 12614467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
    Bonardi R; Tabone M; Manca A; Pellicano R; Ciancio A; Rizzetto M
    Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder-relapser hepatitis C patients: a prospective multicentre randomized controlled study.
    Portal I; Bourlière M; Halfon P; De Lédinghen V; Couzigou P; Bernard PH; Blanc F; Caroli-Bosc F; Arpurt JP; Vetter D; Mathieu-Chandelier C; Chazouillères O; Thiefin G; Pol S; Sogni P; Abergel A; Bailly F; Picon M; Debonne JM; Zamora C; Alleman I; Moreau X; Doll F; Eugène C; Ducloux S; Larrey D; Ouzan D; Grimaud JC; Gouvernet J; Botti G; Gérolami V; Khiri H; Gérolami A; Gauthier AP; Botta-Fridlund D
    J Viral Hepat; 2003 May; 10(3):215-23. PubMed ID: 12753341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daily interferon induction regimen using different manufactured interferons (alpha-2A or alpha-2B) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study.
    Braga EL; Lyra AC; Nascimento L; Netto E; Kalabrik L; Lyra LG
    Arq Gastroenterol; 2006; 43(4):275-9. PubMed ID: 17406754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.